DeepMed Research

Doxazosin

Generic Name: Doxazosin

Brand Names: Cardura

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₅N_₅O_₅

CAS Number: 74191-85-8

Unique Ingredient Identifier: NW1291F1W8

Background: Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include Prazosin, Terazosin, Tamsulosin, and Alfuzosin. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990.

Indication: Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension. Off-label uses of doxazosin include the treatment of pediatric hypertension and the treatment of ureteric calculi.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Hypertension, Ureteric calculus

Clinical Trials

Treating Nightmares in Posttraumatic Stress Disorder with Clonidine and Doxazosin

Phase 2

Recruiting

Conditions: Posttraumatic Stress Disorder

Interventions: Drug: Clonidine
Drug: Doxazosin
Drug: Placebo

First Posted Date: 2022-05-04

Last Posted Date: 2025-01-07

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 189

Registration Number: NCT05360953

Locations: 🇩🇪
Universitätsklinikum Tübingen, Tübingen, Germany
🇩🇪
Berlin St. Hedwig, Berlin, Germany
🇩🇪
Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Psychiatrie und Psychotherapie, Berlin, Germany

and more 2 locations

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Phase 2

Recruiting

Conditions: Alcohol Use Disorder (AUD)

Interventions: Drug: Placebo
Drug: Doxazosin

First Posted Date: 2019-10-23

Last Posted Date: 2024-08-06

Lead Sponsor: Brown University

Target Recruit Count: 184

Registration Number: NCT04135846

Locations: 🇺🇸
Brown University, Providence, Rhode Island, United States

Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL

Phase 1

Withdrawn

Conditions: Alcohol Use Disorder

Interventions: Drug: Doxazosin XL
Drug: Placebo

First Posted Date: 2018-01-12

Last Posted Date: 2022-09-01

Lead Sponsor: The University of Texas Health Science Center, Houston

Registration Number: NCT03398252

A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD

Phase 2

Active, not recruiting

Conditions: Stress Disorders, Post-Traumatic

Interventions: Drug: Doxazosin Mesylate, Extended Release
Drug: Placebo

First Posted Date: 2017-11-13

Last Posted Date: 2024-05-01

Lead Sponsor: San Francisco Veterans Affairs Medical Center

Target Recruit Count: 80

Registration Number: NCT03339258

Locations: 🇺🇸
San Francisco VA Medical Center, San Francisco, California, United States

Preoperative Alpha Blockade for Pheochromocytoma

Phase 3

Completed

Conditions: Paraganglioma
Pheochromocytoma

Interventions: Drug: Phenoxybenzamine
Drug: Doxazosin

First Posted Date: 2017-06-05

Last Posted Date: 2023-11-20

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 39

Registration Number: NCT03176693

Locations: 🇺🇸
University of California, Los angeles, Los Angeles, California, United States

Testing Doxazosin to Treat Stress Mechanisms in Alcoholism

Phase 2

Completed

Conditions: Alcoholism

Interventions: Drug: Doxazosin
Other: Placebo

First Posted Date: 2016-12-12

Last Posted Date: 2021-03-18

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 61

Registration Number: NCT02989493

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Doxazosin and Ramipril in Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Doxazosin
Drug: Ramipril

First Posted Date: 2016-09-15

Last Posted Date: 2025-03-04

Lead Sponsor: Karolinska Institutet

Target Recruit Count: 71

Registration Number: NCT02901977

Locations: 🇸🇪
Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory, Stockholm, Sweden

DOX as a Potential Treatment for Methamphetamine Dependence

Phase 1

Completed

Conditions: Substance-Related Disorders

Interventions: Drug: Sugar Pill
Drug: Doxazosin

First Posted Date: 2016-05-27

Last Posted Date: 2016-09-29

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 11

Registration Number: NCT02785393

Locations: 🇺🇸
Michael Debakey VA Medical Center, Houston, Texas, United States

The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients

Phase 2

Conditions: Hypertension

Interventions: Drug: Doxazosin
Drug: Nifedipine

First Posted Date: 2015-09-30

Last Posted Date: 2016-07-28

Lead Sponsor: First Affiliated Hospital of Harbin Medical University

Target Recruit Count: 30

Registration Number: NCT02563405

Locations: 🇨🇳
uric acid test and 24-hour ambulatory BP monitoring, Harbin, Heilongjiang, China

Complementary Combination Therapy for Cocaine Dependence

Phase 1

Completed

Conditions: Cocaine Dependence

Interventions: Drug: Doxazosin
Drug: Modafinil
Drug: cocaine
Drug: Placebo

First Posted Date: 2015-09-02

Last Posted Date: 2022-04-26

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 45

Registration Number: NCT02538744

Locations: 🇺🇸
Michael Debakey VA Medical Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy